Statins in nephrotic syndrome: A new weapon against tissue injury

Medicinal Research Reviews

Volumn 25, Issue 6, 2005, Pages 587-609

  Buemi, Michele ^a,b,c   Nostro, Lorena ^a,c   Crascì, Eleonora ^a,c   Barillà, Antonio ^a,c   Cosentini, Vincenzo ^a,c   Aloisi, Carmela ^a,c   Sofi, Tito ^a,c   Campo, Susanna ^a,c   Frisina, Nicola ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Department of Nephrology ^*

^c Medical Oncology and Integrated Therapies   (Italy)

Author keywords

Hyperlipidemia; Nephrotic syndrome; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALENDRONIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; COMPACTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LISINOPRIL; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

APOPTOSIS; ARTERIAL PRESSURE; BLOOD VESSEL TONE; BONE TURNOVER; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; INFLAMMATION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; META ANALYSIS; METABOLIC DISORDER; NEOVASCULARIZATION (PATHOLOGY); NEPHROTIC SYNDROME; NONHUMAN; PLEIOTROPY; PROTEINURIA; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TISSUE INJURY;

ANIMALS; BONE REMODELING; DISEASE PROGRESSION; FIBRINOLYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNITY; INFLAMMATION; LIPID METABOLISM; NEOVASCULARIZATION, PHYSIOLOGIC; NEPHROTIC SYNDROME; VASODILATION;

EID: 26844518501     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20040     Document Type: Review

References (154)

1. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reinjngoud DJ, Rabeling TJ. Increased VLDL in nephritic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998;53:994-1001.
2. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990;323:579-584.
3. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 2003;63(5):1964-1976.
4. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979-1985.
5. Liang KH, Oveisi F, Vaziri ND. Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 1996;49:855-860.
6. Vaziri ND, Sato T, Liang K. Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 2003;63:1756-1763.
7. Vaziri ND, Liang K. Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50:887-893.
8. Vaziri ND, Liang KH. Upregulation of Acyl-Coenzyme A: Cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002;61:1769-1775.
9. Vaziri ND, Liang K, Park JS. Acquired lecithin:cholesterol acyltranferase (LCAT) deficiency in nephrotic syndrome. Am J Physiol 2001;49:F823-F829.
10. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001;59(6):2192-2196.
11. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol 2004;287(5):F1038-F1043. Epub 2004 Jul 27.
12. Levy E, Ziv E, Bar-On H, Shafrir E. Experimental nephrotic syndrome: Removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1990;1043:259-266.
13. Garber DW, Gottlieb BA, Marsh JB, Sparks CE. Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 1984;74:1375-1383.
14. Davies RW, Staprans I, Hutchison FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990;86:600-605.
15. Dullaart RP, Gansevoort RT, Dikkeschei BD, de Zeeuw D, de Jong PE, Van Tol A. Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 1993;44:91-97.
16. Braschi S, Masson D, Restorer G, Florentin E, Athias A, Martin C, Gambert P, Lallemant C, Lagrost L. Role of lipoprotein bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. Arterioscler Thromb Vasc Biol 1997;17:2554-2567.
17. Sun X, Jones H Jr, Jones JA, van Tol A, Kaysen GA. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 1992;262:F755-F761.
18. Kaysen GA, Hoye E, Jones H, Jr. Apolipoprotein A I levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol 1995;268:F532-F540.
19. Liang K, Vaziri ND. Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int 1999;56:621-626.
20. Liang K, Vaziri ND. Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 1997;51:1933-1937.
21. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001;59:179-189.
22. Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 1997;130:387-394.
23. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, Yamamoto T, Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 1995;270:15747-15754.
24. Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 1997;51:1761-1765.
25. Sato T, Liang K, Vaziri ND. Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002;61:157-162.
26. Furukawa S, Hirano T, Mamo JC, Nagano S, Takahashi T. Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism 1990;39:101-107.
27. De Sain-van der Velden MG, Reijingould DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, Koomans IIA, Rabclink TJ. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998;9:1474-1481.
28. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44(3):638-642.
29. USRDS. 1999. Annual data report. Am J Kidney Dis 1999;34:S20-S152.
30. Lindner A, Ch'arra B, Sherrard D, Scribner B. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
31. Mittman N, Avram MM. Dyslipidemia in renal disease. Semin Dial 1996;16:202-213.
32. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
33. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309.
34. Joles JA, van Goor H, van Der Horst MLC. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats Lab Invest 1995;73:912-921.
35. Virchow R. A more precise account of fatty metamorphosis. In: Chance F, editor. Cellular pathology. Birmingham: Gryphon Editions; 1860. pp 324-366.
36. Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid depositino in routine biopsies. Clin Nephrol 1991;36:127-133.
37. Mintner P, Coresh J, Smith JC. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis Risk in Communities Study. Kidney Int 2000;58:293-301.
38. Samuelsson O, Attman PO, Knight-Gibson C. Complex apolipoprotein B-containing lipoprotein particles are associates with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482-1488.
39. Tozawa M, Iseki K, Oshiro C, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002;62:1743-1751.
40. Ritz E, Schömig M, Wagner J. Counteracting progression of renal disease: A look into the future. Kidney Int 2000;57(s75):71-76.
41. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, Floccari F, Nostro L, Frisina N. Statins multiple faces: A not only hypocholesterolemizing cardionephrological therapy. Cardionephrology 2002;7(Bios Editoriale):417-424 (Assisi).
42. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389.
43. Saks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
44. O'Keefe JH Jr, Captain BK, Jones PG, Harris WS. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol 2004;7(4):154-160.
45. The Long-Term Intervention of Pravastatin in Ischemic Disease (LIPID). Study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
46. Marchiali R, Marfisi RM. Prevenzione primaria e secondaria della cardiopatia ischemica. Dalla metanalisi e dalla meta-regressione ai meccanismi biologici: Riflessioni per una pratica clinica basata sull'evidenza scientifica. G Ital Cardiol 1998;28:434-459.
47. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, Konig P, Thiery J, Koch M, von Eckardstein A, Dieplinger H. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004;66(1):348-354.
48. Shepherd J, Cobbe SM, Ford I (for the West of Scotland Coronary Prevention Study Group). Prevention of coronary heart disease with pravastatin in men and hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
49. Downs JR, Clearfield M, Weis S (For the Air Force/Texas Coronary Atherosclerosis Prevention Study Group). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1616-1622.
50. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME (for the PLAC I Investigators). Pravastatin limitation of aterosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-1139.
51. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, Frisina N. Are there potential non lipid lowering uses of statins in the kidney? Nephron 2001;89:363-368.
52. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57(7):728-734.
53. Valdivielso P, Moliz M, Valera A, Corrales MA, Sanchez-Chaparro MA, Gonzalez-Santos P. Atorvastatin in dyslipidaemia of the nephrotic syndrome. Nephrology (Carlton) 2003;8(2):61-64.
54. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14(6):1605-1613.
55. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003;64(2):565-571.
56. Rodriguez-Iturbe B, Sato T, Quiroz Y, Vaziri ND. AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. Kidney Int 2004;66(2):668-675.
57. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102(1):52-60. Epub 2004 Apr 2.
58. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304.
59. Tonelli M, Moye' L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138-198:98-104.
60. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309-1311.
61. Kean WF. Lipids and the kidney. Kidney Int 1994;46:910-920.
62. Kasiske BL, O'Donnel MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-672.
63. Cappelli P, Evangelista M, Bonomini M, Palmieri PF, Albertazzi A. Lipids in the progression of chronic renal failure. Nephron 1992;62:31-35.
64. Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, Balletta M, Bellinghieri G, Conte G, Cianciaruso B, Dal Canton A. Effects of hypercholesterolemia on renal hemodynamics: study in patients with nephrotic syndrome. Nephron 1996;73:430-435.
65. Kim S-Y, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractent protein-1: Modulation by lovastatin. Kidney Int 1995;48:363-371.
66. Grandaliano G, Biswas P, Choudhury GC, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993;44:503-508.
67. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, Floccari F, Tramontana D, Frisina N. Statins and progressive renal disease. Med Res Rev 2002;22,1:76-84.
68. Habenicht AJR, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980;255(11):5134-5140.
69. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187-194.
70. Nishida Y, Yorioka N, Oda H, Yamakido M. Effects of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 1997;29:919-930.
71. Hikada Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94.
72. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibition of proliferation of arterial smooth muscle cells by fluvastatin. Lancet 1996;348:1584.
73. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994;24:766-772.
74. Quesncy-Huneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979;76:5056-5060.
75. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
76. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Ocda T, Tahara K, Terano T, Narumiya S, Kohn LD, Saito Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272:13-16.
77. Vrtovsnik F, Couette S, Priè D, Lallemand D, Friendlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997;52:1016-1027.
78. Rogler G, Lackner KJ, Schimtz G. Effects of fuvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 1995;76:114A-116A.
79. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-87.
80. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, Di Pasquale G, Corica F. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999;370:201-203.
81. Senatore M, Buemi M. HMG-CoA reductase inhibitors and apoptosis. Nephron 1999;81:439-440.
82. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernendez G, Egido J. 3-Hydroxy-3-methylglutaril coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
83. Ghosh PM, Mott GE, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI. Lovastatin induces apoptosis by inhibiting mitotic and postmitotic events in cultured mesangial cells. Biochim Biophys Acta 1997;1359:13-24.
84. Buemi M, Corica F, Marino D, Medici MA, Di Pasquale G, Ruello A, Sturiale A, Senatore M, Frisina N. Cardiovascular remodelling, apoptosis and drugs. Am J Hyperten 2000;13:450-454.
85. Savill J. Apoptosis and the kidney. J Am Soc Nephrol 1994;5:12-21.
86. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. The role of altered metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991;17(Suppl 1):38-42.
87. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 1995;48:363-371.
88. Miyazaki K, Isbel NM, Lan HY, Hattori M, Ito K, Bacher M, Bucala R, Atkins RC, Nikolic-Paterson DJ. Up-regulation of macrophage colony-stimulating factor (M-CSF) and migration inhibitory factor (MIF) expression and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolaemic (ExHC) rat. Clin Exp Immunol 1997;108:318-323.
89. B activation in human mesangial cells. Nephrol Dial Transplant 1996;11:990-996.
90. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe MS, Pettinato G, Corsonello A, Senatore M, Frisina N. Effect of fluvastatin on proteinuria in patients with IgA nephropathy. Clin Pharmacol Ther 2000;67:427-431.
91. Fiee LF, Orchard TJ, Kasiske BL. Effect of lipid induction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260-269.
92. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999;56(Suppl 71):S2-S5.
93. Johnson RJ. Cytokines, growth factors and renal injury: Where do we go now? Kidney Int 1997;52(Suppl 63):S2-S6.
94. Downward J. Cell cycle: Routine role for Ras. Curr Biol 1997;7:R258-R260.
95. Fukada Y, Takao T, Ohguro H, Yoshizawa T, Akino T, Shimonishi Y. Farnesylated g-subunit of photoreceptor G protein indispensable for GTP-binding. Nature 1990;364:658-660.
96. Qiu MS, Pitts AF, Winters TR, Green SH. Ras isoprenylation is required for ras-induced but not for NGF-induced neuronal differentiation of PC12 cells. J Cell Biol 1991;115:795-808.
97. Magee T, Marshall C. New insight into the interaction of Ras with the plasma membrane. Cell 1999;98:9-12.
98. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits growth of human H-ras oncogene transformed cells in nude mice. Cancer Comm 1991;60:249-254.
99. Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell M, Kasiske BL, Keane WF, Egido J. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int 1999;56(Suppl 71):S88-S91.
100. Olsson AG, Schwartz GG, Jonasson L, Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiologica Scandinavica 2002;176:147-152.
101. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
102. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 1997;100:2671-2679.
103. Wong B. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959-962.
104. Mach B, Steimle V, Martinez Soria E, Reith W. Regulation of MHC class genes: Lessons from a disease. Annu Rev Immunol 1996;14:301-331.
105. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:1038-1048.
106. Karnelson S, Wilkinson AH, Kobashigawa JA. The effect of pravastatin on acute rejection after kidney transplantation-A pilot study. Transplantation 1996;61:1469-1474.
107. Kasiske BL, Hoirri Duthoy KL, Singer GG. The effects of lipid lowering agoins on acute renal allograft rejection. Transplatation 2001;72:223-227.
108. Holdaas H, Jardine AG, Wheeler DC. Effect of fluvastatin on acute renal allograft rejection a randomized multicenter trial. Kidney Int 2001;60:1990-1997.
109. Sahu K, Sharma R, Gupta A. Effect of lovastatin an HMG CoA reductase inhibitor on acute renal allograft rejection. Clin Transplant 2001;15:173-175.
110. Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, Lemeshow S. Patient survival after renal transplantation III: The effects of statins. Am J of Kidney Dis 2002;40(3):638-643.
111. Mach F. Toward a role for statins in immunomodulation. Mol Interv 2002;2(8):478-480.
112. Orlic D, Kajtura J, Cimenti S. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344-10349.
113. Vasa M, Fichtischere S. Adler Increase in circulating endothelial progenitor cells statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890.
114. Lievadot J, Murasawa S, Kureishi Y. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
115. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statin have biphasic effects on angiogenesis circulation. 2002;105:739-750.
116. Jones SP, Trocha SD, Lefer D. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 2001;21:2059-2064.
117. Shimada T, Takeshita Y, Murohara T, Sasaki K, Egami K, Shintani S, Katsuda Y, Ikeda H, Nabeshima Y, Imaizumi T. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004;110(9):1148- 1155. Epub 2004 Aug 09.
118. Ambrosi P, Aillaud MF, Habib G. Fluvastatin decreases solubile thrombomodulin in cardiac transplant recipients. Thromb Haemost 2000;83:46-48.
119. Juhan-Vague I, Alessi MC. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue. Thromb Haemost 1999;82:832-836.
120. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000;152:359-366.
121. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004;94(4):497-500.
122. Haslinger B, Goedde MF, Toet KH, Kooistra T. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int 2002;62:1611-1617.
123. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: A comparative study using different statins. Br J Pharmacol 2002;135:284-292.
124. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Tromb Res 2002;105:285-290.
125. John S, Schlaich M, Langelfeld M. Increased bioavailability of nitric nitric oxide after lipid lowering therapy in hypercholesterolemic patients a randomized, placebo-controlled, double-blind study. Circulation 1998;98:211-216.
126. Hausberg M, Kosch M, Stam F, Heindenreich S, Kisters K, Rahn KH, Barenbrock M. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001;59:1473-1479.
127. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
128. Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y. Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004;1689(3):267-272.
129. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide syntase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
130. Callahan AS 3rd. Vascular pleiotropy of statins: Clinical evidence and biochemical mechanisms. Curr Atheroscler Rep 2003;5(1):33-37.
131. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85(8):962-968.
132. Wilson TW, Aloncso Galicia M, Roman RJ. Effects of lipid lowering agents in the Dahl salt sensitive rat. Hypertension 1998;31:225-231.
133. Jiang J, Roman RJ. Lovastatin prevents developments of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
134. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G. Effect of combinig ACE inhibitor and statin in severe experimental nephropathy. Kidny Int 2002;61:1635-1645.
135. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;92:2546-2551.
136. Treasure CB, Klein JL, Wientraub WS. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
137. Jarai Z, Kapocsi J, Farsang C, Detki K, Pados G, Sebestyen Z, Hollo J. Effect of fluvastatin on serum lipid levels in essential hypertension. Orv Hetil 1996;137:1857-1859.
138. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): A pilot study. Schweiz Med Wochenschr 1998;128:272-277.
139. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressare in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1288.
140. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40:67-73.
141. Sartor G, Katzman P, Eizyk E, Kalen J, Nilsson A, Ugander L, Ursing D. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995;33:3-6.
142. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, Rila H, Hoogendam I, Van Bortel L. Does lowering of cholesterol, levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995;48:217-223.
143. Krmar RT, Ferraris JR, Ramirez JA, Sorroche P, Legal S, Cayssials A. Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol 2002;17:540-543.
144. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress. Hypertension 2004;44(2):186-190. Epub 2004 Jul 06.
145. Lickam SP, Hughes DE, Coxon FP, Graham R, Russel G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding, including Ras. J Bone Miner Res 1998;13:581-589.
146. Fischer JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russel RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-138.
147. Mundy G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
148. Whang K, Zhao M, Oiao M, Rossini G, Horn D, Garret JR, Mundy GR, Chen D. Administration of lovastatin locally in low doses in a novel delivery system induces prolonged bone formation. J Bone Miner Res 2000;15:8225.
149. Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001;285:1850-1855.
150. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-3216.
151. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomized controlled trial. Long-term intervention with Pravastatin in Ischaemic Disease. Lancet 2001;357:509-512.
152. Funkhouser HL, Adera T, Adler RA. Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J Clin Densitom 2002;5(2):151-158.
153. Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001;285:1850-1855.
154. Futterman LG, Lemberg L. Statin pleiotropy: Fact or fiction? Am J Crit Care 2004;13(3):244-249.